GANT61

目录号:S8075 别名: NSC 136476

仅限科研使用

GANT61 (NSC 136476)是一种GLI1及GLI2诱导的转录抑制剂,抑制hedgehog,在表达GLI1的HEK293T细胞中IC50为5 μM,选择性作用于其他通路,如TNF和糖皮质激素受体基因的转录。GANT61在LX-2细胞中可诱导凋亡并激活保护性自噬。

GANT61 Chemical Structure

CAS: 500579-04-4

规格 价格 库存 购买数量
RMB 1215.87 现货
RMB 4661.51 现货
大包装 有超大折扣

今日订购,明日送达 全国免运费 分装免费 分装成小规格产品(单支最小为1mg)
如1支10mg产品可分装为10支1mg产品

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的GANT61发表文献80篇:

产品安全说明书

Hedgehog/Smoothened抑制剂选择性比较

相关Hedgehog/Smoothened产品

生物活性

产品描述 GANT61 (NSC 136476)是一种GLI1及GLI2诱导的转录抑制剂,抑制hedgehog,在表达GLI1的HEK293T细胞中IC50为5 μM,选择性作用于其他通路,如TNF和糖皮质激素受体基因的转录。GANT61在LX-2细胞中可诱导凋亡并激活保护性自噬。
靶点
GLI1 [1]
(HEK293T cells expressing GLI1)
5 μM
体外研究

GANT61抑制GLI1及GLI2诱导的转录。GANT61抑制GLI1的DNA结合能力。GANT61抑制hedgehog信号,IC50为5 μM,比作用于其他通路选择性高,如TNF信号/NFκB激活,糖皮质激素受体基因转录,及Ras-Raf-Mek-Mapk级联。GANT61在体外有效抑制肿瘤细胞增殖,这种作用存在GLI依赖性。[1]GANT61作用于慢性淋巴细胞性白血病细胞(CLL),而非正常的B淋巴细胞,诱导细胞凋亡。[2]GANT61作用于人结肠癌细胞系,具有强大的细胞毒性,且废除集落生成。[3]GANT61作用于人结肠癌细胞系的早S期阶段,抑制DNA复制,产生涉及ATM-Chk2信号轴的DNA损伤信号,且诱导细胞死亡。[4] GANT61 (30 μM)作用于急性髓系白血病(AML)细胞,导致生长停滞和凋亡。[5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Shh Light2 M{HQfWZ2dmO2aX;uJIF{e2G7 MV3Jcohq[mm2aX;uJI9nKFOKSDDpckBud3W|ZTDTbIghVGmpaISyJINmdGy|IHL5JGdNUS2{ZYPwc45{cX[nIH\pdoVndHlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBKSzVyIE2gOUDPxE1w M2niVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{C5NFgxLz5zOUOwPVA5ODxxYU6=
Shh-L2 M2mwemZ2dmO2aX;uJIF{e2G7 NUD6fYJHUW6qaXLpeIlwdiCxZjDI[YRo\WixZzDzbYdv[WyrbnegbY4hcHWvYX6gV4hpNUx{IHPlcIx{NCCLQ{WwJF0hPSEQvF2u NIDlW3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{S5OFc3Pid-MUe0PVQ4PjZ:L3G+
NIH 3T3 NHnVN|VHfW6ldHnvckBie3OjeR?= M13qWWlvcGmkaYTpc44hd2ZiSHigd4lodmGuaX7nJJBifGi5YYmgbY4hW2iqLVzJS2hVOiCrbnPvdpBwemG2ZXSgcY92e2ViTlnIJFNVOyClZXzsd{Bie3Onc4Pl[EBieyCmb4fudoVofWyjdHnvckBw\iCJbHmxJIdmdmViZYjwdoV{e2mxbjDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVAhRSB3IN88UU4> NIW1SWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm3OlIyPSd-Mk[5O|YzOTV:L3G+
HeLa MWHGeY5kfGmxbjDhd5NigQ>? NEDhdIQ1NjViaILz MWLJcohq[mm2aX;uJI9nKEWkb3zheolzfXNiZ3z5Z49xem:2ZXnuM41ifHKreDDwdo91\WmwIG\QOFAh\W62comgbY4hcHWvYX6gTIVN[SClZXzsd{Bi\nSncjC0MlUhcHK|IHLleIEudGGldHHtZZNmKHKncH;yeIVzKGG|c3H5MEBKSzVyIE2gOk45OyEQvF2u M{LWUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkK0N|g4Lz5{OU[yOFM5PzxxYU6=
TM3 NVHPfId{TnWwY4Tpc44h[XO|YYm= MWm0PEBpenN? MmizTY5pcWKrdHnvckBw\iCKaDDzbYdv[WyrbnegdIF1cHejeTDpckBud3W|ZTDUUVMh[2WubIOgZZN{\XO|ZXSgZZMh\G:5boLl[5Vt[XSrb36gc4YhT2yrMTDn[Y5mKGW6cILld5Nqd25iYX\0[ZIhPDhiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OCB;IEmuNlch|ryPLh?= MlnUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7N{[yNVUoRjJ4OUe2NlE2RC:jPh?=
Rh30 MX;GeY5kfGmxbjDhd5NigQ>? MVqyOEBpenN? M2rnOGlvcGmkaYTpc44hd2ZiaIXtZY4hT2yrMT3t[YRq[XSnZDD0doFve2O{aYD0bY9v[WxiYXP0bZZqfHliaX6gbJVu[W5iUnizNEBk\WyuczDh[pRmeiB{NDDodpMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBKSzVyIE2gOFAh|ryPLh?= Ml2yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4MEW3NlAoRjJyNkC1O|IxRC:jPh?=
HEK293 NFHL[otHfW6ldHnvckBie3OjeR?= NXr1U4E6WmWmdXP0bY9vKG:oIFfMTVIhdWWmaXH0[YQhfHKjboPjdolxfGmxbjDpckBJTUt{OUOgZ4VtdHNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBie3OjeR?= MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzR7NEe2Okc,OTd2OUS3OlY9N2F-
NIH3T3 NH7rcmNHfW6ldHnvckBie3OjeR?= NH\GenBKdmirYnn0bY9vKG:oIFfMTVEhcW6mdXPl[EBp\WSpZXjv[{B{cWewYXzpcochcW5ibX;1d4UhVkmKM2SzJINmdGy| NED2XpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{S5OFc3Pid-MUe0PVQ4PjZ:L3G+
HEK293 MmDJSpVv[3Srb36gZZN{[Xl? NUfkVm1TUW6qaXLpeIlwdiCxZjDi[ZRiKGejbHHjeI9{cWSjc3WgbY4hUEWNMkmzJINmdGy| M{\DblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NEm0O|Y3Lz5zN{S5OFc3PjxxYU6=
MEF NXTDemxOTnWwY4Tpc44h[XO|YYm= M3TDTHJm\HWldHnvckBqdiCneIDy[ZN{cW:wIH;mJGhm\GenaH;nJJRiemendDDn[Y5mKEircEGgbY4hW3WodTDk[YZq[2mnboSgcY92e2ViTVXGJINmdGy| NVrLOmVzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0PVQ4PjZpPkG3OFk1PzZ4PD;hQi=>
NIH3T3 NYrlbXJ3TnWwY4Tpc44h[XO|YYm= NVfQUFk6OTBidV2= M{fmOWlvcGmkaYTpc44hd2ZiSHXk[4Vpd2dxR3zpNUBu\WSrYYTl[EB1emGwc3\vdo1ifGmxbjDpckBud3W|ZTDOTWg{XDNiY3XscJMh[XRiMUCgeW0> NHv4WlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{S5OFc3Pid-MUe0PVQ4PjZ:L3G+
PANC1 NH7J[2pHfW6ldHnvckBie3OjeR?= M4ezSlUhfU1? MVzS[YR2[3Srb36gbY4hT0yLMTDlfJBz\XO|aX;uJIlvKGi3bXHuJHBCVkNzIHPlcIx{KGG2IEWgeW0> MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzR7NEe2Okc,OTd2OUS3OlY9N2F-
PANC1 NUfpVWlyTnWwY4Tpc44h[XO|YYm= MorSOUB2VQ>? NETiTo1T\WS3Y4Tpc44hcW5iUGTDTEBmgHC{ZYPzbY9vKGmwIHj1cYFvKFCDTlOxJINmdGy|IHH0JFUhfU1? MmnkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2OUS3OlYoRjF5NEm0O|Y3RC:jPh?=
22Rv NHzrdJFHfW6ldHnvckBie3OjeR?= MYe1JJVO NVTGOnA3WmWmdXP0bY9vKGmwIFfsTVEh\XiycnXzd4lwdiCrbjDoeY1idiB{MmL2JINmdGy|IHH0JFUhfU1? MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzR7NEe2Okc,OTd2OUS3OlY9N2F-
22Rv NEjPOXFHfW6ldHnvckBie3OjeR?= MVS1JJVO NVf1WW83WmWmdXP0bY9vKGmwIGDUR2gh\XiycnXzd4lwdiCrbjDoeY1idiB{MmL2JINmdGy|IHH0JFUhfU1? NYfMUW4xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0PVQ4PjZpPkG3OFk1PzZ4PD;hQi=>
22Rv MkDSSpVv[3Srb36gZZN{[Xl? NIO0SFJT\WS3Y4Tpc44hd2ZiZYjwdoV{e2mxbjDv[kBRXEOKIH3SUmEhcW5iaIXtZY4hOjKUdjDj[Yxtew>? MojaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2OUS3OlYoRjF5NEm0O|Y3RC:jPh?=
HEK293 MXfGeY5kfGmxbjDhd5NigQ>? M4mxR2lvcGmkaYTpc44hd2ZiboXjcIVieiCjY3P1cZVt[XSrb36gc4YhT0yLIH31eIFvfCCrbjDISWszQTNiY3XscJM> NH\vcGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{S5OFc3Pid-MUe0PVQ4PjZ:L3G+
HEK293 NVLhZ3pFTnWwY4Tpc44h[XO|YYm= NH\ZXFVKdmirYnn0bY9vKG:oIH71Z4xm[XJiYXPjeY12dGG2aX;uJI9nKHerbHSgeJlx\SCJTFmgbY4hUEWNMkmzJINmdGy| MkTuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2OUS3OlYoRjF5NEm0O|Y3RC:jPh?=
HEK293 NWrGXmI5TnWwY4Tpc44h[XO|YYm= NGXCV3ZT\WS3Y4Tpc44hd2ZiR1zJNUBu\WSrYYTl[EB1emGwc3PybZB1cW:wIHnuJGhGUzJ7MzDj[YxteyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIF{e2G7 NFe4eYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{S5OFc3Pid-MUe0PVQ4PjZ:L3G+
22Rv NFLL[FhCdnSrdIXtc5Ih[XO|YYm= M4f0PFUxKG2pL3vn MYOxPEBl[Xm| NUnYWXZISW62aYT1cY9zKGGldHn2bZR6KGmwIFfMTVEheG:|aYTpeoUhcHWvYX6gNlJTfiClZXzsd{B5\W6xZ4Lh[pRm\CCvb4Xz[UBud2SnbDDheEA2OCCvZz;r[{whe2NiYX\0[ZIhOThiZHH5dy=> MmPDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2OUS3OlYoRjF5NEm0O|Y3RC:jPh?=
HEK293 MXLGeY5kfGmxbjDhd5NigQ>? MmOwN|AhfU1? NEjqdW9KdmirYnn0bY9vKG:oIFfMTUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIFfMTU1u\WSrYYTl[EB1emGwc3PybZB1cW:wIHH0JFMxKHWP M4PJZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUixNFE4Lz5{NUW4NVAyPzxxYU6=
A673 MWHxTHRUKGG|c3H5 M4DlPJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| NEHvV|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-MC NUHlfmJoeUiWUzDhd5NigQ>? M3HzRpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz NGPMTm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB-EBc1 NH;TSWtyUFSVIHHzd4F6 Mk\UdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ|Eh[2WubIO= MkG4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
OHS-50 NFPZTHFyUFSVIHHzd4F6 Mnv4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= NUe1dGQxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD MonndWhVWyCjc4PhfS=> MV7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM> MkPVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-DZ MV\DfZRwfG:6aXPpeJkh[XO|YYm= NFTvTJI4OiCqcoO= M17uZ2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMNU5vRGqgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KG[udX;yc41mfHKrYzDtbYNzd2O3bIT1doUh[3m2b4TvfIlkcXS7IHHzd4F6NCCJSUWwJF0hPS56MjFOwG0v MoKyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFcyPzJ6Lze+R4hGVUKOPD;hQi=>
SK-N-SH MVHDfZRwfG:6aXPpeJkh[XO|YYm= NXy5RY5rPzJiaILz NVO0[pI1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0tvTj3TTEBk\WyuczDh[pRmeiB5MjDodpMh[nliZnz1c5JwdWW2cnnjJI1q[3KxY4XseJVz\SCleYTveI95cWOrdImgZZN{[XluIFfJOVAhRSB3LkiyJO69VS5? M3ywTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OTd{OD:nQmNpTU2ETEyvZV4>
SK-N-FI NH3vfYhEgXSxdH;4bYNqfHliYYPzZZk> M2PNVlczKGi{cx?= NELuV|VEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUy2QLV\JJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCobIXvdo9u\XS{aXOgcYlkem:ldXz0eZJmKGO7dH;0c5hq[2m2eTDhd5NigSxiR1m1NEA:KDVwOEKg{txONg>? NH;MeGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzF5MkivK|5EcEWPQly8M4E,
SK-N-AS NGXCTWZEgXSxdH;4bYNqfHliYYPzZZk> NEG4T2E4OiCqcoO= NELpNZlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUy2QLVHTJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCobIXvdo9u\XS{aXOgcYlkem:ldXz0eZJmKGO7dH;0c5hq[2m2eTDhd5NigSxiR1m1NEA:KDVwOEKg{txONg>? M{K2TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OTd{OD:nQmNpTU2ETEyvZV4>
IMR32 NFPqb2VEgXSxdH;4bYNqfHliYYPzZZk> NHHmTJQ4OiCqcoO= MY\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDJUXI{OiClZXzsd{Bi\nSncjC3NkBpenNiYomg[ox2d3KxbXX0dolkKG2rY4LvZ5VtfHW{ZTDjfZRwfG:6aXPpeJkh[XO|YYmsJGdKPTBiPTC1MlgzKM7:TT6= NYfpRYtFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDdzN{K4M{c,S2iHTVLMQE9iRg>?
SK-N-BE(2) M3S0dGN6fG:2b4jpZ4l1gSCjc4PhfS=> Ml;rO|IhcHK| NV63dI1tS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0tvTj3CSUgzMSClZXzsd{Bi\nSncjC3NkBpenNiYomg[ox2d3KxbXX0dolkKG2rY4LvZ5VtfHW{ZTDjfZRwfG:6aXPpeJkh[XO|YYmsJGdKPTBiPTC1MlgzKM7:TT6= NG\0bGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzF5MkivK|5EcEWPQly8M4E,
SH-SY5Y M1n2SGN6fG:2b4jpZ4l1gSCjc4PhfS=> MmnOO|IhcHK| MlvhR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2guW1l3WTDj[YxteyCjZoTldkA4OiCqcoOgZpkh\my3b4LvcYV1emmlIH3pZ5Jw[3WudIXy[UBkgXSxdH;4bYNqfHliYYPzZZktKEeLNUCgQUA2Njh{IN88UU4> M1jvSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OTd{OD:nQmNpTU2ETEyvZV4>
Assay
Methods Test Index PMID
Western blot GLI1 / p-STAT3 / STAT3 / SOCS3 GLI2 / Bcl-2 27275540 25544756
Immunofluorescence Gli2 24533083
Growth inhibition assay Cell viability 27275540
体内研究 GANT61处理注射GLI1-阳性22Rv1前列腺癌细胞的裸鼠,诱导肿瘤生长衰退,直到观察不到明显的肿瘤。[1]GANT61按50 mg/kg剂量口服饲喂处理携带SK-N-AS神经母细胞瘤移植瘤的裸鼠,在实验第12天显著抑制肿瘤生长,与对照组相比,肿瘤体积减少63%。[6]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
  • 双荧光素酶含量:

    转染GLI1表达质粒的HEK293细胞与报告质粒12×GliBSLuc 和R-Luc 一起置于10 cm板上(实验第0天)。24小时后,细胞接种按每孔15,000个细胞的密度接种在白色透明底的96孔板中。细胞粘附,加入溶于DMSO(DMSO终浓度为0.5% ) 的终浓度为10 μM的化合物加(实验第1.5天)。细胞再生长24小时,随后裂解,然后使用双荧光素酶试剂盒进行分析。

细胞实验:[1]
  • Cell lines: PANC1 或 22Rv1
  • Concentrations: ~5 μM
  • Incubation Time: 48 小时
  • Method: 进行BrdU渗透实验。在有5 μM 实验化合物 (或 DMSO) 存在下,亚融合的细胞在含FBS(2.5%)的白色透明底的96孔板上生长48小时。随后,使用BrdU对细胞进行标记2小时,混合,然后分析。
动物实验:[1]
  • Animal Models: 携带22Rv1细胞移植瘤的BALB/c裸鼠
  • Dosages: 50 mg/kg
  • Administration: 皮下注射

溶解度(25°C)

体外

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 429.6
化学式

C27H35N5

CAS号 500579-04-4
储存条件 3年 -20°C 粉状
2年 -80°C 溶于溶剂

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量 浓度 体积 分子量

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们
Tags: buy GANT61 | GANT61 supplier | purchase GANT61 | GANT61 cost | GANT61 manufacturer | order GANT61 | GANT61 distributor